Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
61 hedge funds and large institutions have $30M invested in Sio Gene Therapies Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 13 closing their positions.
32% more capital invested
Capital invested by funds: $22.8M → $30M (+$7.25M)
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
0% more funds holding
Funds holding: 61 → 61 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
4% less call options, than puts
Call options by funds: $234K | Put options by funds: $245K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$18M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$14.8M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$1.8M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.05M |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$795K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$394K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$327K |
| 3 |
VEA
Virtus ETF Advisers
New York
|
-$301K |
| 4 |
Goldman Sachs
New York
|
-$221K |
| 5 |
State Street
Boston,
Massachusetts
|
-$207K |
SIOX Hedge Fund Activity: Q4 2018 in Review
61 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q4 2018, worth a combined $30M — up 32% from $22.8M a quarter earlier.
Fund positioning in SIOX was balanced in Q4 2018: 13 funds opened new positions, 13 closed out, 17 added to existing stakes and 14 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $18M. The largest seller was Connor, Clark & Lunn Investment Management (CC&L), cutting an estimated $394K.
- 61 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $30M of Sio Gene Therapies Inc. Common Stock stock for Q4 2018, up 32% quarter-over-quarter.
- 13 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q4 2018 and 13 closed out, a net change of 0 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q4 2018 was Deerfield Management, an estimated $18M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q4 2018 was Connor, Clark & Lunn Investment Management (CC&L), an estimated $394K sold.
Based on aggregated 13F filings for Q4 2018.